Daniela is a Professor of Vaccinology in the Oxford Vaccine Group, Department of Paediatrics, University of Oxford. Daniela is a global leader in Respiratory Infections and Controlled Human Infection Challenge with experience in bacterial challenge, co-infection studies, vaccine trials and mucosal immunity (nose and lungs). She leads a Programme of work on respiratory infections and vaccine development currently funded by BMGF, UKRI, NIHR and top global pharma. She leads the unique Experimental Human Pneumococcal Consortium in partnership with over 50 laboratories of worldwide experts on respiratory infection and pneumococcal biology. Her team has played a substantial role in the UK covid-19 pandemic response including being a trial site for the Phase II/III of the Oxford / Astrazeneca vaccine and heterologous prime-boost studies (COM-COV). Her research focuses mainly on: 1) Accelerate development and test novel pneumococcal vaccines using experimental carriage 2) understanding nasal and lung immune responses and correlates of protection against respiratory infections with viruses including SARS-CoV2 and bacteria 3) defining how respiratory virus co-infections (flu, RSV and SARS-CoV2) and host susceptibility (asthma, COPD, aging, smoke) alters responses to pneumococcal infection Daniela obtained a PhD in Immunology in 2009 from the University of Sao Paulo (São Paulo, Brazil). From 2001 to 2009 Daniela trained at Butantan Institute (Sao Paulo, Brazil) on development of novel vaccines against respiratory infections using different formulations, new adjuvants and routes of immunization. During her PhD Daniela was awarded the prestigious Robert Austrian Research Award in Pneumococcal Vaccinology to develop novel nasal vaccines (2006). Daniela joined the Liverpool School of Tropical Medicine in 2009 as a postdoctoral scientist and was promoted to Professor and Head of department in 2018. Twitter: danielalstm